Literature DB >> 17671690

Paracrine interactions of vascular endothelial growth factor and platelet-derived growth factor in endothelial and lung cancer cells.

Niels Reinmuth1, Sonja Rensinghoff, Miriam Raedel, Nicole Fehrmann, Christian Schwöppe, Torsten Kessler, Guido Bisping, Frank Hilberg, Gerald J Roth, Wolfgang Berdel, Michael Thomas, Rolf M Mesters.   

Abstract

While the effects of single growth factors on endothelial cells (ECs) have been extensively studied, the importance of induction of growth factors such as PDGF-BB (platelet derived growth factor) in ECs and its impact on tumor cell functions are only partly understood. Human umbilical vein endothelial cells (HUVECs) were cultured under serum-free conditions and stimulated by 20 ng/ml VEGF (vascular endothelial growth factor) or 20 ng/ml bFGF (basic fibroblastic growth factor). As determined by real-time PCR, both VEGF and bFGF induced a significant (up to 4-fold) increase in PDGF-B RNA expression which was time- and dose-dependent (p<0.05). Similarly, conditioned medium (CM) from lung cancer cells (A549) which is known to contain multiple growth factors including VEGF and bFGF also induced PDGF-B RNA expression. Using ELISA assays, VEGF and bFGF significantly increased PDGF-BB protein secretion in HUVECs (p<0.01). By addition of BIBF 1000, a novel inhibitor of the VEGF and bFGF receptor kinases, the effect of VEGF on PDGF-B RNA induction was significantly antagonized (p<0.01). Furthermore, we studied the biological significance of EC-derived PDGF-BB on lung cancer cells. Interestingly, HUVEC-derived CM significantly stimulated migration of A549 cells (p<0.001) with a trend to further increased migration with the use of VEGF-stimulated (PDGF-BB rich) CM (p=0.2). Collectively, endothelial and lung cancer cells seem to interact via various paracrine pathways, e.g. by the reciprocal induction of VEGF and PDGF-BB. Thus, targeting key molecules would result in expression alterations of multiple factors and alter the biological functions of both stromal and tumor cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17671690

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  7 in total

Review 1.  VEGF non-angiogenic functions in adult organ homeostasis: therapeutic implications.

Authors:  Jincai Luo; Yan Xiong; Xiaofan Han; Yao Lu
Journal:  J Mol Med (Berl)       Date:  2011-03-02       Impact factor: 4.599

2.  Sunitinib prolongs survival in genetically engineered mouse models of multistep lung carcinogenesis.

Authors:  Leena Gandhi; Kate L McNamara; Danan Li; Christa L Borgman; Ultan McDermott; Kathleyn A Brandstetter; Robert F Padera; Lucian R Chirieac; Jeffrey E Settleman; Kwok-Kin Wong
Journal:  Cancer Prev Res (Phila)       Date:  2009-03-31

3.  Key Common Genes in Obstructive Sleep Apnea and Lung Cancer are Associated with Prognosis of Lung Cancer Patients.

Authors:  Wenjun Wang; Lirong He; Chao Ouyang; Chong Chen; Xiaofeng Xu; Xiaoqun Ye
Journal:  Int J Gen Med       Date:  2021-09-07

4.  Lysophosphatidic acid enhances vascular endothelial growth factor-C expression in human prostate cancer PC-3 cells.

Authors:  Chuan-En Lin; Shee-Uan Chen; Chu-Cheng Lin; Chi-Hao Chang; Yueh-Chien Lin; Yu-Ling Tai; Tang-Long Shen; Hsinyu Lee
Journal:  PLoS One       Date:  2012-07-20       Impact factor: 3.240

5.  VEGF expression by mesenchymal stem cells contributes to angiogenesis in pancreatic carcinoma.

Authors:  B M Beckermann; G Kallifatidis; A Groth; D Frommhold; A Apel; J Mattern; A V Salnikov; G Moldenhauer; W Wagner; A Diehlmann; R Saffrich; M Schubert; A D Ho; N Giese; M W Büchler; H Friess; P Büchler; I Herr
Journal:  Br J Cancer       Date:  2008-07-29       Impact factor: 7.640

6.  Comparison of angiogenesis-related factor expression in primary tumor cultures under normal and hypoxic growth conditions.

Authors:  Jamie M Heinzman; Stacey L Brower; Jason E Bush
Journal:  Cancer Cell Int       Date:  2008-07-10       Impact factor: 5.722

7.  Engineering a 3D microfluidic culture platform for tumor-treating field application.

Authors:  Andrea Pavesi; Giulia Adriani; Andy Tay; Majid Ebrahimi Warkiani; Wei Hseun Yeap; Siew Cheng Wong; Roger D Kamm
Journal:  Sci Rep       Date:  2016-05-24       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.